ATE469128T1 - Indole, die sich zur behandlung von mit dem androgenrezeptor in zusammenhang stehenden krankheiten eignen - Google Patents

Indole, die sich zur behandlung von mit dem androgenrezeptor in zusammenhang stehenden krankheiten eignen

Info

Publication number
ATE469128T1
ATE469128T1 AT03810458T AT03810458T ATE469128T1 AT E469128 T1 ATE469128 T1 AT E469128T1 AT 03810458 T AT03810458 T AT 03810458T AT 03810458 T AT03810458 T AT 03810458T AT E469128 T1 ATE469128 T1 AT E469128T1
Authority
AT
Austria
Prior art keywords
alkyl
alkoxy
halogen
optionally substituted
androgen receptor
Prior art date
Application number
AT03810458T
Other languages
English (en)
Inventor
Pedro Harold Han Hermkens
Herman Thijs Stock
Neeltje Miranda Teerhuis
Johannes Petrus Maria Lommerse
Der Louw Jaap Van
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE469128T1 publication Critical patent/ATE469128T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03810458T 2002-11-07 2003-11-03 Indole, die sich zur behandlung von mit dem androgenrezeptor in zusammenhang stehenden krankheiten eignen ATE469128T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42457902P 2002-11-07 2002-11-07
EP02079648 2002-11-07
PCT/EP2003/050783 WO2004041782A1 (en) 2002-11-07 2003-11-03 Indoles useful in the treatment of androgen-receptor related diseases

Publications (1)

Publication Number Publication Date
ATE469128T1 true ATE469128T1 (de) 2010-06-15

Family

ID=42635437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03810458T ATE469128T1 (de) 2002-11-07 2003-11-03 Indole, die sich zur behandlung von mit dem androgenrezeptor in zusammenhang stehenden krankheiten eignen

Country Status (15)

Country Link
EP (1) EP1585727B1 (de)
JP (1) JP4643989B2 (de)
CN (1) CN100391944C (de)
AT (1) ATE469128T1 (de)
AU (1) AU2003301853B2 (de)
BR (1) BR0316020A (de)
CA (1) CA2504907C (de)
ES (1) ES2344836T3 (de)
NZ (1) NZ539657A (de)
PL (1) PL376728A1 (de)
RS (1) RS20050340A (de)
RU (1) RU2328484C2 (de)
TW (1) TWI310032B (de)
UA (1) UA79504C2 (de)
WO (1) WO2004041782A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200602317A (en) * 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
DE102004047272A1 (de) * 2004-09-24 2006-04-06 Schering Ag Inhibitoren der löslichen Adenylatzyklase
DE102005027274A1 (de) * 2005-06-08 2006-12-14 Schering Ag Inhibitoren der löslichen Adenylatzyklase
US7417066B2 (en) 2005-06-08 2008-08-26 Schering Ag Inhibitors of soluble adenylate cyclase
MX2007015905A (es) * 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
WO2007073231A1 (en) * 2005-12-23 2007-06-28 Victor Lvovoch Limonov Agent for treating tumoral diseases, a method for the production thereof and a method for treating tumoral diseases
DE102006014324B4 (de) 2006-03-23 2009-01-08 Bayer Schering Pharma Aktiengesellschaft Inhibitoren der löslichen Adenylatzyklase
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
WO2008042571A2 (en) 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
RU2408592C2 (ru) * 2008-12-31 2011-01-10 Федеральное государственное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" (ЮФУ) Гидрогалогениды 3-[1-(2-гидрокси-3-пиперидин-1-ил-пропил)-1н-индол-3-ил]-1-фенил-пропенона, обладающие местноанестезирующей и антиаритмической активностью
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RS67458B1 (sr) 2014-03-28 2025-12-31 Univ Duke Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
CN113861186B (zh) * 2021-09-10 2023-08-25 浙江师范大学 基于异恶唑取代苯甲酰胺类衍生物及抗前列腺癌药物应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ179580A (en) * 1974-12-30 1978-04-03 Mcneilab Inc 2-or 3-(w-tertiaryaminoalkyl)-thioindoles and the corresponding sulfinyl and sulfonyl analogs
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
GB9204365D0 (en) * 1992-02-28 1992-04-08 Pfizer Ltd Indoles
EP1501826B1 (de) * 2002-02-01 2006-09-27 F. Hoffman-la Roche AG Substituierte indole als alpha-1 agonisten
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
RU2005117374A (ru) 2006-01-20
WO2004041782A1 (en) 2004-05-21
RS20050340A (sr) 2007-06-04
AU2003301853A1 (en) 2004-06-07
PL376728A1 (pl) 2006-01-09
CN100391944C (zh) 2008-06-04
CN1714078A (zh) 2005-12-28
JP4643989B2 (ja) 2011-03-02
TW200418793A (en) 2004-10-01
ES2344836T3 (es) 2010-09-08
RU2328484C2 (ru) 2008-07-10
AU2003301853B2 (en) 2010-02-18
CA2504907A1 (en) 2004-05-21
CA2504907C (en) 2011-10-11
JP2006507293A (ja) 2006-03-02
TWI310032B (en) 2009-05-21
EP1585727A1 (de) 2005-10-19
BR0316020A (pt) 2005-09-20
UA79504C2 (en) 2007-06-25
NZ539657A (en) 2008-04-30
EP1585727B1 (de) 2010-05-26

Similar Documents

Publication Publication Date Title
PL376728A1 (pl) Indole użyteczne do leczenia chorób związanych z receptorem androgenowym
ATE292628T1 (de) Chinazolinderivate
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
DE60322267D1 (de) Chinolinderivate als glucokinase liganden
BRPI0413233A (pt) novos compostos
DE69823843D1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
DE602004016174D1 (de) Substituierte indazolyl(indolyl)maleimid-derivate als kinase inhibitoren
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
ATE235465T1 (de) Antiimflammatorische indolderivate
ATE405266T1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
DE60326232D1 (de) Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
PE20011008A1 (es) Derivados de pirimidina como inhibidores de ciclooxigenasa 2
EA200702058A1 (ru) Новые фармацевтические соединения
ATE261941T1 (de) Heterocyclische amide als inhibitoren von faktor xa
EA200602288A1 (ru) Замещённые тиазолуксусные кислоты в качестве лигандов crth2
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
NO995935D0 (no) 17<beta>-allyloksy(tio)alkyl-androstan-derivater for modulering av meiose
CO5580758A2 (es) Indoles utiles en el tratamiento de enfermedades relaciona das con androgenos receptores
ATE293591T1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
AR026244A1 (es) Compuestos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties